1062 related articles for article (PubMed ID: 29104284)
21. Targeting JAK-STAT signal transduction in IBD.
Soendergaard C; Bergenheim FH; Bjerrum JT; Nielsen OH
Pharmacol Ther; 2018 Dec; 192():100-111. PubMed ID: 30048708
[TBL] [Abstract][Full Text] [Related]
22. JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases.
Gao Q; Liang X; Shaikh AS; Zang J; Xu W; Zhang Y
Curr Drug Targets; 2018; 19(5):487-500. PubMed ID: 27928945
[TBL] [Abstract][Full Text] [Related]
23. A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Liu C; Kieltyka J; Fleischmann R; Gadina M; O'Shea JJ
Arthritis Rheumatol; 2021 Dec; 73(12):2166-2178. PubMed ID: 34180156
[TBL] [Abstract][Full Text] [Related]
24. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
25. New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis.
D'Urso DF; Chiricozzi A; Pirro F; Calabrese L; Caldarola G; Fossati B; De Simone C; Peris K
G Ital Dermatol Venereol; 2020 Aug; 155(4):411-420. PubMed ID: 32545945
[TBL] [Abstract][Full Text] [Related]
26. JAK-STAT inhibitors for the treatment of immunomediated diseases.
Serra López-Matencio JM; Morell Baladrón A; Castañeda S
Med Clin (Barc); 2019 May; 152(9):353-360. PubMed ID: 30527218
[TBL] [Abstract][Full Text] [Related]
27. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
[TBL] [Abstract][Full Text] [Related]
28. Newer treatments of psoriasis regarding IL-23 inhibitors, phosphodiesterase 4 inhibitors, and Janus kinase inhibitors.
Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Bebenek K; Kaźmierczak A
Dermatol Ther; 2017 Nov; 30(6):. PubMed ID: 28994166
[TBL] [Abstract][Full Text] [Related]
29. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
30. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition.
Luo Y; Alexander M; Gadina M; O'Shea JJ; Meylan F; Schwartz DM
J Allergy Clin Immunol; 2021 Oct; 148(4):911-925. PubMed ID: 34625141
[TBL] [Abstract][Full Text] [Related]
31. Novel Therapeutic Approaches in Rheumatoid Arthritis: Role of Janus Kinases Inhibitors.
Rivellese F; Lobasso A; Barbieri L; Liccardo B; de Paulis A; Rossi FW
Curr Med Chem; 2019; 26(16):2823-2843. PubMed ID: 29424301
[TBL] [Abstract][Full Text] [Related]
32. JAK inhibitors for asthma.
Georas SN; Donohue P; Connolly M; Wechsler ME
J Allergy Clin Immunol; 2021 Oct; 148(4):953-963. PubMed ID: 34625142
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of JAK/STAT signaling in rheumatologic disorders: The expanding spectrum.
El Jammal T; Gerfaud-Valentin M; Sève P; Jamilloux Y
Joint Bone Spine; 2020 Mar; 87(2):119-129. PubMed ID: 31521793
[TBL] [Abstract][Full Text] [Related]
34. Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?
Kotyla PJ
Biomed Res Int; 2018; 2018():7492904. PubMed ID: 29862290
[TBL] [Abstract][Full Text] [Related]
35. Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis.
Garufi C; Maclean M; Gadina M; Spinelli FR
Expert Rev Clin Immunol; 2022 Mar; 18(3):309-319. PubMed ID: 35168456
[TBL] [Abstract][Full Text] [Related]
36. Molecular Structure and Function of Janus Kinases: Implications for the Development of Inhibitors.
Garrido-Trigo A; Salas A
J Crohns Colitis; 2020 Aug; 14(Supplement_2):S713-S724. PubMed ID: 32083640
[TBL] [Abstract][Full Text] [Related]
37. JAK Inhibitors: Prospects in Connective Tissue Diseases.
You H; Xu D; Zhao J; Li J; Wang Q; Tian X; Li M; Zeng X
Clin Rev Allergy Immunol; 2020 Dec; 59(3):334-351. PubMed ID: 32222877
[TBL] [Abstract][Full Text] [Related]
38. Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.
Zak M; Dengler HS; Rajapaksa NS
Bioorg Med Chem Lett; 2019 Oct; 29(20):126658. PubMed ID: 31522830
[TBL] [Abstract][Full Text] [Related]
39. Thromboembolic Adverse Drug Reactions in Janus Kinase (JAK) Inhibitors: Does the Inhibitor Specificity Play a Role?
Kotyla PJ; Engelmann M; Giemza-Stokłosa J; Wnuk B; Islam MA
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671049
[TBL] [Abstract][Full Text] [Related]
40. Exploring the role of Janus kinase (JAK) in atopic dermatitis: a review of molecular mechanisms and therapeutic strategies.
Kogame T; Egawa G; Kabashima K
Immunol Med; 2023 Sep; 46(3):112-120. PubMed ID: 37254967
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
